# US 2014/0155426 A1 · Pharmaceutical formulation containing irritant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155426 A1
- Document ID: US20140155426A1
- Status: Published application
- Kind: A1
- Application number: 14/148,909
- Filed: 2014-01-07
- Published: 2014-06-05
- Earliest claimed: 2001-08-06
- Assignees: Purdue Pharma L.P.
- Applicants: Purdue Pharma L.P.
- Inventors: Richard Sackler
- Web page: https://patentgrep.com/patent/US20140155426A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/5078: {with drug-free core}
- A61K 9/5089: {Processes}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

## Claims

### Claim 1

An oral dosage form comprising:
a therapeutically effective amount of a drug susceptible to abuse; and
an effective amount of an irritant to impart a burning sensation to an abuser upon inhalation or injection of said dosage form after crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof.

### Claim 2 (depends on 1)

The oral dosage form of claim 1, wherein the irritant is selected from the group consisting of capsaicin, a capsaicin analog, and mixtures thereof.

### Claim 3 (depends on 1)

The oral dosage form of claim 1, wherein the irritant is a capsaicin analog selected from the group consisting of resiniferatoxin, tinyatoxin, heptanoylisobutylamide, heptanoyl guaiacylamide, other isobutylamides or guaiacylamides, dihydrocapsaicin, homovanillyl octylester, nonanoyl vanillylamide, and mixtures thereof.

### Claim 4 (depends on 1)

The oral dosage form of claim 1, wherein the irritant is capsaicin.

### Claim 5 (depends on 1)

The oral dosage form of claim 1, wherein the irritant is vanillylamide.

### Claim 6 (depends on 1)

The oral dosage form of claim 1, wherein the irritant is in a sequestered form.

### Claim 7

(canceled)

### Claim 8 (depends on 6)

The oral dosage form of claim 6, wherein said irritant is dispersed in a matrix comprising a sequestering material that substantially prevents the release of said irritant.

### Claim 9 (depends on 1)

The oral dosage form of claim 1, wherein said drug is an opioid analgesic.

### Claim 10 (depends on 9)

The oral dosage form of claim 9, wherein said opioid analgesic is morphine, codeine, tramadol, or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 11 (depends on 9)

The oral dosage form of claim 9, wherein said opioid analgesic is hydromorphone or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 9)

The oral dosage form of claim 9, wherein said opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 9)

The oral dosage form of claim 9, wherein said opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The oral dosage form of claim 1, wherein said drug is selected from the group consisting of a tranquilizer, a CNS depressant, a CNS stimulant, a sedative hypnotic, or combinations thereof.

### Claim 15 (depends on 1)

The oral dosage form of claim 1, wherein said burning sensation is provided after said inhalation of said dosage form after said crushing, shearing, grinding, or chewing.

### Claim at position 16

16-17. (canceled)

### Claim 18 (depends on 1)

The oral dosage form of claim 1, wherein the irritant is in an amount of about 0.00125% to about 50% by weight of the dosage form.

### Claim 19 (depends on 1)

The oral dosage form of claim 1, wherein the irritant is in an amount of about 1 to about 7.5% by weight of the dosage form.

### Claim 20 (depends on 1)

The oral dosage form of claim 1, wherein the irritant is in an amount of about 1 to about 5% by weight of the dosage form.

### Claim at position 20

21-28. (canceled)

### Claim 29 (depends on 1)

The oral dosage form of claim 1 which consists of said drug, said irritant, a modified or sustained release carrier, and one or more pharmaceutical excipients.

### Claim 30 (depends on 1)

The oral dosage form of claim 1, wherein said burning sensation is provided after said inhalation of said dosage form after said crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof.
